|
|
Volumn 56, Issue 6, 2017, Pages 865-868
|
|
Corrigendum: BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs [Rheumatology, 56, (2017) (865-868)] doi:10.1093/rheumatology/kew479;BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
a b b c c d b e f g h i j k l |
|
Author keywords
Co morbidity; DMARDs; Drug toxicity; Methotrexate; Rheumatic disease; Safe prescribing; Shared care; Treatment monitoring
|
|
Indexed keywords
APREMILAST;
AUROTHIOMALATE;
AZATHIOPRINE;
CYCLOSPORIN A;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
HYDROXYCHLOROQUINE;
LEFLUNOMIDE;
MEPACRINE;
METHOTREXATE;
MINOCYCLINE;
MYCOPHENOLATE MOFETIL;
SALAZOSULFAPYRIDINE;
TACROLIMUS;
ANTIRHEUMATIC AGENT;
BLOOD ANALYSIS;
COMORBIDITY;
DRUG MONITORING;
EVIDENCE BASED MEDICINE;
HUMAN;
INFECTION;
LABORATORY TEST;
MEDICAL SOCIETY;
NOTE;
PATIENT CARE;
PERIOPERATIVE PERIOD;
PRACTICE GUIDELINE;
PRESCRIPTION;
PRIORITY JOURNAL;
RHEUMATIC DISEASE;
ANTIRHEUMATIC AGENTS;
DRUG MONITORING;
DRUG PRESCRIPTIONS;
HUMANS;
RHEUMATIC DISEASES;
|
|
EID: 85021148730
PISSN: 14620324
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/kex389 Document Type: Erratum |
|
Times cited : (95)
|
|
References (3)
|
